The immune-evasive yet druggable nature of IGF2BP1 in ovarian cancer cells suggests that inhibiting IGF2BP1-RNA interactions with small-molecule inhibitors such as BT or CUB may enhance T cell-mediated tumor cell killing. The gene discussed is IGF2BP1; the disease is neoplasm.